PCVX — Vaxcyte, Inc.

—
Nasdaq · Health Care · Biotechnology · CIK 1649094 ·
Last close
$59.40
Market Cap
$9.40B
52W High
$90.75
52W Low
$42.40
ADV30
2,392,666
Next earnings
2026-11-04

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -308,274,000 -297,062,000 2,989,136,000 125,470,000 499,918,000
Jun 2026 0 — -302,777,000 -284,302,000 3,138,154,000 183,190,000 380,212,000
Mar 2026 0 — -345,850,000 -320,622,000 3,348,308,000 260,843,000 352,294,000
Dec 2025 0 — -274,283,000 -246,507,000 3,002,717,000 173,959,000 317,207,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-962,009,000
Investing CF
$200,205,000
Financing CF
$604,366,000
CapEx
$-32,750,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-7.82
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-3,056,933,000
Inventory
—
Receivables
—
ST Investments
$1,166,759,000
EBIT TTM
$-1,231,184,000
Pretax Income TTM
$-1,148,493,000
Interest Exp TTM
—
Analysts
10

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -923,675,000 -766,628,000 3,002,717,000 317,207,000 2,685,510,000 -655,577,000
Dec 2024 0 -569,546,000 -463,927,000 3,511,318,000 205,499,000 3,305,819,000 -452,627,000
Dec 2023 0 -393,041,000 -402,266,000 1,407,917,000 167,449,000 1,240,468,000 -296,790,000
Dec 2022 0 -209,261,000 -223,485,000 1,006,178,000 52,565,000 953,613,000 -170,597,000

TTM Snapshot

Revenues TTM
$108,075,000
NetIncome TTM
$-1,064,261,000
OpCashFlow TTM
—
Assets (Latest)
$3,138,154,000
Forward EPS
$-7.15

Max Pain — expiry 2026-12-18

max pain strike: $55.00 · spot: $58.52 · call oi: 16,154 · put oi: 43,620
Expected Move to 2026-12-18: ±$7.25 (12.39%) — implied range $51.27 – $65.77 · ATM straddle on $60.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
KRYS Krystal Biotech, Inc. $8.85B $298.55 —
QGEN QIAGEN N.V. $10.27B $49.75 —
RGEN REPLIGEN CORP $10.30B $162.18 —
KYMR Kymera Therapeutics, Inc. $10.37B $121.52 —
HALO HALOZYME THERAPEUTICS, INC. $10.94B $95.97 —

News headlines (Yahoo Finance, 1h cache)

3 High Growth Stocks With At Least 33% Earnings Growth
2026-11-09 23:17 · Yahoo
Vaxcyte Reports Third Quarter 2026 Financial Results and Provides Business Update
2026-11-04 21:05 · Yahoo
Wall Street Analysts See an 87.35% Upside in Vaxcyte (PCVX): Can the Stock Really Move This High?
2026-10-30 12:55 · Yahoo
Wall Street Analysts Think Vaxcyte (PCVX) Could Surge 75.6%: Read This Before Placing a Bet
2026-10-14 12:55 · Yahoo
Why Vaxcyte (PCVX) Is Getting Attention Again
2026-10-08 18:15 · Yahoo
Vaxcyte Announces Pricing of Concurrent Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes
2026-10-07 02:48 · Yahoo
Biotech Stocks Tumble, With Recent Winners Moderna, Vaxcyte Among The Biggest Losers
2026-10-06 20:34 · Yahoo
As Expected: Vaxcyte Announces $1 Billion Stock and Convertible Raise a Day After Its Phase 3 Win (and Sinks 10%)
2026-10-06 15:31 · Yahoo
Vaxcyte VAX-31 pneumococcal vaccine phase 3 trial results
2026-10-06 12:44 · Yahoo
Vaxcyte’s VAX-31 Meets All Primary Endpoints in Pivotal Phase III OPUS-1 Trial
2026-10-06 02:02 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.